These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28393712)

  • 21. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus.
    Ohno Y; Okumura T; Terada R; Ishihara S; Serikawa T; Sasa M
    Neurosci Lett; 2012 Feb; 510(2):93-8. PubMed ID: 22266237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).
    Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD
    Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential expression of SV2A in hippocampal glutamatergic and GABAergic terminals during postnatal development.
    Vanoye-Carlo A; Gómez-Lira G
    Brain Res; 2019 Jul; 1715():73-83. PubMed ID: 30905653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low distribution of synaptic vesicle protein 2A and synaptotagimin-1 in the cerebral cortex and hippocampus of spontaneously epileptic rats exhibiting both tonic convulsion and absence seizure.
    Hanaya R; Hosoyama H; Sugata S; Tokudome M; Hirano H; Tokimura H; Kurisu K; Serikawa T; Sasa M; Arita K
    Neuroscience; 2012 Sep; 221():12-20. PubMed ID: 22766234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [
    Xiao L; Xiang S; Chen C; Zhu H; Zhou M; Tang Y; Feng L; Hu S
    Psychiatry Clin Neurosci; 2024 Aug; 78(8):456-467. PubMed ID: 38804583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.
    Mercier J; Archen L; Bollu V; Carré S; Evrard Y; Jnoff E; Kenda B; Lallemand B; Michel P; Montel F; Moureau F; Price N; Quesnel Y; Sauvage X; Valade A; Provins L
    ChemMedChem; 2014 Apr; 9(4):693-8. PubMed ID: 24446373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Connectivity Mapping Using a Novel
    Zhang Y; Heylen L; Partoens M; Mills JD; Kaminski RM; Godard P; Gillard M; de Witte PAM; Siekierska A
    Front Mol Neurosci; 2022; 15():881933. PubMed ID: 35686059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Down-regulation synaptic vesicle protein 2A in the anterior temporal neocortex of patients with intractable epilepsy.
    Feng G; Xiao F; Lu Y; Huang Z; Yuan J; Xiao Z; Xi Z; Wang X
    J Mol Neurosci; 2009 Nov; 39(3):354-9. PubMed ID: 19757204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.
    Contreras-García IJ; Gómez-Lira G; Phillips-Farfán BV; Pichardo-Macías LA; García-Cruz ME; Chávez-Pacheco JL; Mendoza-Torreblanca JG
    Brain Sci; 2021 Apr; 11(5):. PubMed ID: 33922424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brivaracetam prevents astroglial l-glutamate release associated with hemichannel through modulation of synaptic vesicle protein.
    Okada M; Fukuyama K; Shiroyama T; Ueda Y
    Biomed Pharmacother; 2021 Jun; 138():111462. PubMed ID: 33706129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.
    Douaud M; Feve K; Pituello F; Gourichon D; Boitard S; Leguern E; Coquerelle G; Vieaud A; Batini C; Naquet R; Vignal A; Tixier-Boichard M; Pitel F
    PLoS One; 2011; 6(10):e26932. PubMed ID: 22046416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Epilepsy-Associated SV2A Mutation Disrupts Synaptotagmin-1 Expression and Activity-Dependent Trafficking.
    Harper CB; Small C; Davenport EC; Low DW; Smillie KJ; Martínez-Mármol R; Meunier FA; Cousin MA
    J Neurosci; 2020 Jun; 40(23):4586-4595. PubMed ID: 32341095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
    Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
    Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.